Phenylpiracetam (fonturacetam) is piracetam with a phenyl ring added, developed in the Soviet Union and sold in Russia as Phenotropil for asthenia and cerebrovascular disease.
Amounts reported for Phenylpiracetam are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 1 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Meta-analysis of Russian asthenia studies549 patients with asthenia (mean age 45.9) across 11 studies | 200 mg per day | Daily | Oral | One month, assessed on day 30None described | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2025 |
| Every included study used the same 200 mg a day, and the pooled MFI-20 asthenia score fell by 16.3 points after a month, with side effects in 5.5 percent of patients that resolved within a week of continued treatment. The analysis was published in a Russian journal about the branded product, and the underlying studies were mostly open and small, so the effect size is uncertain. | |||||
| Stroke rehabilitation programme400 patients with ischaemic stroke, 200 of whom received phenotropil | 400 mg per day | Daily during each course | Oral | 3 courses over the year after strokeBreaks between the three courses, length not stated in the abstract | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2010 |
| Recovery of neurological function and daily living scores was reported as significantly better in the treated group. The abstract does not describe randomisation or blinding, and the dose is twice the 200 mg a day used in the asthenia studies. | |||||
| Observational programme in chronic brain ischaemia (TRIUMPH)1170 primary-care patients aged 45-65 with chronic brain ischaemia and asthenic syndrome | 100 mg | Daily | Oral | 2-3 monthsNone described | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2014 |
| Asthenia scores on the MFI-20 fell significantly by the end of the first month and kept falling, with a more than two-fold reduction at 3 months and faster responses in younger patients. This was a non-interventional observational programme without a control group, so it describes the course of treated patients rather than a treatment effect. | |||||
| Add-on trial in focal epilepsy90 adults with symptomatic locally induced epilepsy on standard antiepileptic drugs | 100 or 200 mg | Daily | Oral | Not stated in the abstractNone described | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2014 |
| In this double-blind, placebo-controlled randomised trial, phenotropil reduced seizure frequency and improved cognitive scores in patients without epileptiform EEG abnormalities, while leaving the negative effects of standard therapy unchanged in 40 percent of patients. It is one of the few blinded trials of the compound. | |||||
| Preclinical1 row | |||||
| Enantiomer comparison in miceMice in open-field, forced swim and passive avoidance tests | R-enantiomer 1 mg/kg for memory; 10 and 50 mg/kg for locomotion; 50-100 mg/kg for antidepressant effects | Single administration | Systemic | AcuteNot applicable | Basic and Clinical Pharmacology and Toxicology (PubMed)2011 |
| Only the R-enantiomer improved passive-avoidance memory, while both enantiomers raised locomotor activity and reduced immobility in the forced swim test, despite reaching similar brain concentrations. Since market product is the racemate, half of each milligram is the S-form, which had no memory effect in this study. | |||||
| Community-reported3 rows | |||||
| Community dosing and tolerance pattern | 100 mg once or twice daily for cognition; 200 mg as a single dose 1-2 hours before a demanding task | Once or twice daily, morning or morning and early afternoon | Oral capsule or tablet | Intermittent use, 2-3 times a week or short 1-2 week cyclesRapid tolerance reported by day 5-7 of daily use, so breaks are built in | Community resource2026 |
| This 2026 compound page reports that the stimulant and motivational effects fade within a week of daily dosing, lists insomnia, irritability and headache as common complaints, and warns tested athletes that the compound is a WADA-prohibited stimulant. The tolerance pattern comes from user reports; the Russian trials used fixed daily doses for a month and did not report on it. | |||||
| Evidence summary with cycling guidance | 100-200 mg once or twice daily; 100-300 mg per day quoted as the typical range | Once or twice daily, before noon | Oral, often paired with alpha-GPC or citicoline | 2-3 weeks on1-2 weeks off to limit tolerance | Community resource2026 |
| This March 2026 editorial page frames phenylpiracetam as 20-60 times more potent than piracetam by weight, repeats the rapid-tolerance warning and states that it is the same compound as phenotropil and fonturacetam, not approved by the FDA or EMA. The potency multiplier and cycle lengths are the editors' summary of community practice rather than trial findings. | |||||
| Vendor research-use listing (sold as the hydrazide) | 150 mg per capsule of phenylpiracetam hydrazide; a separate 250 mcg aerosol spray is also listed | Not stated (sold for laboratory research only) | Oral capsule format, plus an aerosol spray | Not statedNot stated | Community resource2026 |
| Vendor claim. The vendor's phenylpiracetam listing is actually phenylpiracetam hydrazide, a different molecule in which the amide is replaced by a hydrazide, supplied as 150 mg capsules with an ISO 17025 certificate for lot PH01 (153.17 mg measured); the page nonetheless quotes the CAS number and 218.3 g/mol mass of phenylpiracetam itself. None of the human studies above used the hydrazide, and the page gives no dosing information. | |||||
Community pages describe 100 mg in the morning, or 200 mg before a demanding task, with effects felt within an hour and the stimulant lift fading by day 5-7 of daily use.
Guides either switch to 2-3 uses a week or run 2-3 weeks on followed by 1-2 weeks off. No study has examined tolerance or any cycling schedule.
The Russian studies used a fixed 200 mg a day for 30 days in asthenia, 100 mg a day for 2-3 months in chronic brain ischaemia and 400 mg a day in repeated courses after stroke, all in patients and without reporting tolerance.
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Phenylpiracetam (fonturacetam) is piracetam with a phenyl ring added, developed in the Soviet Union and sold in Russia as Phenotropil for asthenia and cerebrovascular disease. Its human evidence is almost entirely Russian-language: a 2025 meta-analysis of the newer brand Actitropil pooled 11 studies of 549 patients given 200 mg a day for a month, and larger stroke and chronic ischaemia programmes used 100-400 mg a day. It was the first nootropic banned in sport, prohibited by anti-doping authorities as a stimulant since 1998, and it is not approved in the United States or the European Union.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
Every included study used the same 200 mg a day, and the pooled MFI-20 asthenia score fell by 16.3 points after a month, with side effects in 5.5 percent of patients that resolved within a week of continued treatment..
Recovery of neurological function and daily living scores was reported as significantly better in the treated group. The abstract does not describe randomisation or blinding, and the dose is twice the 200 mg a day used.
Asthenia scores on the MFI-20 fell significantly by the end of the first month and kept falling, with a more than two-fold reduction at 3 months and faster responses in younger patients. This was a non-interventional.
In this double-blind, placebo-controlled randomised trial, phenotropil reduced seizure frequency and improved cognitive scores in patients without epileptiform EEG abnormalities, while leaving the negative effects of.
Only the R-enantiomer improved passive-avoidance memory, while both enantiomers raised locomotor activity and reduced immobility in the forced swim test, despite reaching similar brain concentrations. Since market.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
4 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
1 protocol row describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
3 rows record what blogs, vendor write-ups or forums describe for Phenylpiracetam. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Fonturacetam, Phenotropil, Carphedon, 4-Phenylpiracetam, Carphedone, Karfedon, 2-Oxo-4-phenyl-1-pyrrolidineacetamide, UNII 99QW5JU66Y
LYONXVJRBWWGQO-UHFFFAOYSA-N
2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide
8 curated references, each with its journal, year and study model, plus 3 community resources reported but not linked.